H3N2 Infection - Pipeline Review, H1 2016

  • ID: 3643171
  • Report
  • 107 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AIMM Therapeutics B.V.
  • Crucell N.V.
  • Johnson & Johnson
  • MedImmune, LLC
  • NanoViricides, Inc.
  • OPKO Health, Inc.
  • MORE
H3N2 Infection - Pipeline Review, H1 2016

Summary

The report ‘H3N2 Infection - Pipeline Review, H1 2016’, provides an overview of the H3N2 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
- The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects
- The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for H3N2 Infection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AIMM Therapeutics B.V.
  • Crucell N.V.
  • Johnson & Johnson
  • MedImmune, LLC
  • NanoViricides, Inc.
  • OPKO Health, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

H3N2 Infection Overview

Therapeutics Development

Pipeline Products for H3N2 Infection - Overview

Pipeline Products for H3N2 Infection - Comparative Analysis

H3N2 Infection - Therapeutics under Development by Companies

H3N2 Infection - Therapeutics under Investigation by Universities/Institutes

H3N2 Infection - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

H3N2 Infection - Products under Development by Companies

H3N2 Infection - Products under Investigation by Universities/Institutes

H3N2 Infection - Companies Involved in Therapeutics Development

AIMM Therapeutics B.V.

Aphios Corporation

Crucell N.V.

CSL Limited

Glide Pharmaceutical Technologies Limited

ILiAD Biotechnologies, LLC

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Medicago Inc.

MedImmune, LLC

Mucosis B.V.

NanoViricides, Inc.

Novavax, Inc.

OPKO Health, Inc.

Sarepta Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

Visterra, Inc.

Zydus Cadila Healthcare Limited

H3N2 Infection - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

APP-0205 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

APP-309 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

C-05 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CR-8020 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CR-9114 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FluGEM - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gamma-Flu - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H3N2] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H3N2] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JNJ-872 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NVINF-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NVINF-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis [strain BPZE1] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PNSIA-28 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

radavirsen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for RSV and Influenza A Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TXB-248 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VIS-410 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

H3N2 Infection - Recent Pipeline Updates

H3N2 Infection - Dormant Projects

H3N2 Infection - Product Development Milestones

Featured News & Press Releases

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for H3N2 Infection, H1 2016

Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016

H3N2 Infection - Pipeline by Aphios Corporation, H1 2016

H3N2 Infection - Pipeline by Crucell N.V., H1 2016

H3N2 Infection - Pipeline by CSL Limited, H1 2016

H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016

H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016

H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016

H3N2 Infection - Pipeline by Medicago Inc., H1 2016

H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016

H3N2 Infection - Pipeline by Mucosis B.V., H1 2016

H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016

H3N2 Infection - Pipeline by Novavax, Inc., H1 2016

H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016

H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016

H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

H3N2 Infection - Pipeline by Visterra, Inc., H1 2016

H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016

H3N2 Infection - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for H3N2 Infection, H1 2016

Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AIMM Therapeutics B.V.
Aphios Corporation
Crucell N.V.
CSL Limited
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
NanoViricides, Inc.
Novavax, Inc.
OPKO Health, Inc.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Visterra, Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll